In order to bolster its cell therapy pipeline, Sanofi has entered into a collaboration with Scribe Therapeutics to leverage the latter’s CRISPR technology to develop natural killer (NK) cell therapies for multiple oncology targets. The deal will grant Sanofi a non-exclusive license to Scribe’s CasX-Editor (XE) technology in exchange for a US$25 M upfront payment with the potential for more than US$1 B in milestone payments, and tiered royalties. Since its buyout of Kiadis Pharma in 2020, Sanofi has been committed to bringing novel, off-the-shelf NK cell therapies to market.